<DOC>
	<DOCNO>NCT00972140</DOCNO>
	<brief_summary>The purpose study demonstrate clinical equivalence formoterol-HFA pMDI 12µg/actuation administered twice daily formoterol DPI 12µg/capsule deliver Aerolizer inhaler administer twice daily patient COPD .</brief_summary>
	<brief_title>Formoterol-HFA 3-month Study Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description>Phase III , multicenter , multinational , double-blind , double-dummy , randomised , 2-arm parallel-group , 3-month study patient stable COPD . Comparison term efficacy safety two formulation formoterol administered 24µg/day bid regimen</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male female patient give write informed consent . Diagnosis stable COPD accord recommendation Diagnosis stable COPD accord recommendation National Heart Lung Blood Institute ( NHLBI ) Global Initiative Chronic Obstructive Lung Disease ( GOLD ) criterion , Edition 2003 Age 40 year old . Male female patient give write informed consent History progressive nature symptom complaint dyspnoea least exertion . Current previous smoker [ case cumulative exposure cigarette smoke 20 packyears Prebronchodilator baseline 40 % &gt; FEV1 &lt; 70 % predict normal value Absolute value FEV1 &gt; 0.9 L. FEV1/FVC &lt; 70 % ( ERS criterion predict normal value ) . FEV1 reversibility test 30 minute follow inhalation 400 μg salbutamol pMDI A cooperative attitude ability train use correctly pMDI Aerolizer® inhaler Female subject : pregnant , lactate mother lack efficient contraception subject childbearing potential ( e.g . contraceptive method oral contraceptive , IUD , tubal ligature ) . Current past diagnosis asthma . History allergic rhinitis atopic disease ( e.g . eczema ) . Largely reversible airflow obstruction . Onset obstructive symptom early life ( i.e . childhood ) . Variability symptoms day day frequent symptom night early morning . A total blood eosinophil count high 500/μL . Significant unstable concomitant cardiovascular , renal , hepatic , gastrointestinal , neurological , endocrine , metabolic , musculoskeletal , neoplastic , respiratory clinically significant disease Clinical significant laboratory abnormality indicate significant unstable concomitant disease . QTc interval ( Bazett formula ) high 460 msec Total 24 hour respiratory symptom score ( daytime nighttime ) &gt; 2 least 4 consecutive day Lower respiratory tract infection within one month screen visit Hospitalisation emergency room treatment acute COPD exacerbation month screen visit Longterm oxygen therapy . Patients treat oral injectable corticosteroid antibiotic COPD exacerbation and/or lower respiratory tract infection month precede screen visit runin period study . Patients treat depot corticosteroid three month precede screen visit 14week study period . Changes dose , schedule , formulation product inhale nasal corticosteroid oral modifiedrelease theophylline within one month screen visit 14 week study period Patients treat inhaled longacting β2agonists 14week study period . Shortacting β2agonists regular use 14week study period 8 hour precede screen visit Shortacting anticholinergic medication 14week study period Longacting anticholinergic medication ( e.g . tiotropium ) 14week study period . Inhaled fixed combination shortacting β2agonist shortacting anticholinergic medication ( e.g . Combivent ) 14week study period Inhaled fixed combination inhale corticosteroid longacting β2agonist ( e.g.Seretide , Symbicort ) 14week study period . Longacting antihistamine ( e.g . Astemizole , Terfenadine ) three month precede screen visit 14week study period . Tricyclic antidepressant , monoamine oxidase inhibitor ( MAOI ) drug know prolong QTc interval 14week study period . βblockers week precede screen visit 14week study period . Intolerance inhale β2adrenergic agent . History intolerance allergic reaction pMDI DPI excipients . Patients evidence alcohol substance abuse , compliant study protocol compliant study treatment . Participation another clinical trial investigational drug four week precede screen visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Patients stable COPD</keyword>
</DOC>